Patent SG-11201907889Y-A (SG)
Title: Glycan-interacting compounds and methods of use
Inventor: DRANSFIELD DANIEL T
IPC: C07K16/46
Filed: 2018-03-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIP0 I PCT omit VIII °nolo omioolloimoliono iflo oimIE (10) International Publication Number WO 2018/160909 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61K 38/17 (2006.01) CO7K 16/46 (2006.01) (21) International Application Number: PCT/US2018/020562 (22) International Filing Date: 02 March 2018 (02.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,766 03 March 2017 (03.03.2017) US 62/480,126 31 March 2017 (31.03.2017) US 62/486,826 18 April 2017 (18.04.2017) US 62/563,718 27 September 2017 (27.09.2017) US 62/577,830 27 October 2017 (27.10.2017) US (71) Applicant: SIAMAB THERAPEUTICS, INC. [US/US]; 90 Bridge Street, Suite 100, Newton, Massachusetts 02458 (US). = (72) Inventors: DRANSFIELD, Daniel T.; 14 George Street, Hanson, Massachusetts 02341 (US). PRENDERGAST, Jillian M.; 18 Park Street, Maynard, Massachusetts 01754 (US). EAVARONE, David A.; 95 West Squantum Street, Apt 1118, North Quincy, Massachusetts 02171 (US). (74) Agent: WARD, Donna T. et al.; 142A Main Street, Groton, Massachusetts 01450 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE Fig. 2 Serum An Concentrations Following Day 1 Administration 11 01 O 01 O SO 11 0.01 10) - .4(r) 400 600 Time (tat} 1-1 (57) : Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels. O [Continued on next page] WO 2018/160909 Al MIDEDIMOMOIDEIREEMOMOHINIMMONHOMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))